Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Gevo, Inc. (NASDAQ: GEVO) shares spiked 10.57 percent to close at $1.36 a share last Wednesday. The stock traded between $1.23 and $1.38 on volume 3.90 million shares traded. In December, the company announced that that the U.S. Army has successfully flown the Sikorsky UH-60 Black Hawk helicopter on a 50/50 blend of Gevo's ATJ-8 (Alcohol-to-Jet). Shares of Gevo have fallen approximately 5.0 percent year-to-date.
Get more information on Gevo and free access to the in-depth equity report at:
Meritor Inc. (NYSE: MTOR) shares jumped 9.55 percent to close at $10.55 a share last Wednesday. The stock traded between $9.43 and $10.63 on volume of 5.60 million shares traded. The company reported a GAAP net income for the first quarter of fiscal 2014, compared to a net loss of $21.0 million a year ago. Shares of Meritor have gained over 100.0 percent in the past year.
Get more information on Meritor and free access to the in-depth equity report at:
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) shares tumbled 27.42 percent to close at $4.50 a share last Wednesday. The stock traded between $4.31 and $5.48 on volume of 7.80 million shares traded, nearly seven times its average daily volume. According to Bloomberg, two patients have died in a recent study of the company’s experimental prostate cancer treatment. Shares of Progenics Pharmaceuticals have gained over 50.0 percent in the past year.
Get more information on Progenics Pharmaceuticals and free access to the in-depth equity report at:
Prothena Corporation PLC (NASDAQ: PRTA) shares gained 9.76 percent to close at $29.79 a share last Wednesday. The stock traded between $26.75 and $30.10 on volume 1.55 million shares traded. The company announced the pricing of an underwritten public offering of 2.77 million ordinary shares of Prothena at a price to the public of $26.00 per ordinary share. Shares of Prothena have gained approximately 12.0 percent year-to-date.
Get more information on Prothena free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities